Rhythm Biosciences Validates ColoSTAT® Test Pathway, Poised for Rapid Scale-Up
Rhythm Biosciences has completed the first commercial sale of its ColoSTAT® blood test for colorectal cancer, confirming the full clinical and logistical process is operational and ready for expansion.
- First commercial sale of ColoSTAT® colorectal cancer blood test completed
- Validated end-to-end clinical and logistical pathway in routine settings
- Partnership with 4Cyte Pathology enables sample collection and processing
- Immediate scale-up planned via direct physician engagement and ColoSTAT® Access Program
- Initial adoption across five clinical sites in Victoria and New South Wales
Milestone Achievement in Cancer Diagnostics
Rhythm Biosciences Ltd (ASX:RHY) has reached a significant commercial milestone with the first sale of its ColoSTAT® blood-based test designed to detect colorectal cancer. This achievement confirms that the company’s diagnostic test is not only scientifically validated but also fully operational within the clinical environment, encompassing sample collection, transport, assay processing, and result reporting.
Seamless Integration into Clinical Workflows
The successful completion of this initial commercial test involved collaboration with 4Cyte Pathology, which collected patient blood samples and transported them to Rhythm’s laboratory in Parkville, Victoria. The ColoSTAT® test, which measures five protein biomarkers associated with colorectal cancer risk, was processed and results delivered back to the ordering clinician, demonstrating a fully functional end-to-end pathway within a routine healthcare setting.
Scaling Up Through Physician Networks
With the logistical and operational framework validated, Rhythm is now positioned to rapidly increase test volumes. The company plans to expand distribution directly through primary care physicians and via its recently launched ColoSTAT® Access Program, which provides a structured entry point for clinicians to order the test. Early adoption is already underway, with five sites across Victoria and New South Wales participating in the program.
Strategic Implications and Market Potential
Colorectal cancer remains a leading cause of cancer mortality worldwide, and early detection is critical for improving patient outcomes. Rhythm’s blood test offers a less invasive, more accessible alternative to traditional screening methods, potentially reducing healthcare costs and saving lives. The company’s CEO, Dr David Atkins, emphasised that the infrastructure and partnerships are in place to support scaling and that commercial progress will be closely monitored through quarterly updates.
Looking Ahead
Rhythm Biosciences’ successful commercial launch of ColoSTAT® marks a pivotal step in its journey to transform cancer diagnostics. The company’s ability to integrate its test into existing clinical workflows and scale rapidly could position it as a key player in the growing precision medicine and early cancer detection markets.
Bottom Line?
Rhythm’s validated ColoSTAT® test pathway sets the stage for accelerated growth in colorectal cancer diagnostics.
Questions in the middle?
- How quickly will test volumes grow across additional clinical sites beyond the initial five?
- What pricing and reimbursement strategies will Rhythm pursue to drive adoption?
- How will ColoSTAT® compete with existing colorectal cancer screening methods in the market?
